APTEVO ACHIEVES KEY CLINICAL DEVELOPMENT OBJECTIVE, SIGNIFICANTLY REDUCING INFUSION-RELATED REACTIONS WITH MIPLETAMIG IN FRONTLINE AML

Reuters · 4d ago

Please log in to view news